Figure S5 from Systemic LRG1 expression in melanoma is associated with disease progression and recurrence

Autor: Christian U. Blank, Maarten Altelaar, Reinhard Dummer, Dirk Schadendorf, Georgina V. Long, Alexander C.J. van Akkooi, Liesbeth Hoekman, Judith M. Versluis, Irene L.M. Reijers, Elisa A. Rozeman, Franziska Völlmy, Esmee P. Hoefsmit

Figure S5 shows that complement factor B (CFB), component 7 (C7) and alpha-1B-glycoportein (A1BG) expression are increased upon melanoma progression and recurrence.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eff2f8a8ef3578e8d03ed12f2d2bff3
https://doi.org/10.1158/2767-9764.22546879.v1

Data from Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells

Autor: Christian U. Blank, Daniel S. Peeper, Roderick L. Beijersbergen, Maarten A. Ligtenberg, Huma Shehwana, Ruben Lacroix, Irene L.M. Reijers, Elisa A. Rozeman, Ben Morris, Cor Lieftink, P. Dimitriadis, Johanna A. Stunnenberg, Disha Rao, Paula T. van Royen, Esmée P. Hoefsmit

Cross-presentation of tumor antigens by dendritic cells (DC) is crucial to prime, stimulate and restimulate CD8+ T cells. This process is important in initiating and maintaining an antitumor response. Here, we show that the presence of conventional t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6247d5543ce080fea60bf7d3302ea7b4
https://doi.org/10.1158/2326-6066.c.6534796

Figure S2 from Systemic LRG1 expression in melanoma is associated with disease progression and recurrence

Autor: Christian U. Blank, Maarten Altelaar, Reinhard Dummer, Dirk Schadendorf, Georgina V. Long, Alexander C.J. van Akkooi, Liesbeth Hoekman, Judith M. Versluis, Irene L.M. Reijers, Elisa A. Rozeman, Franziska Völlmy, Esmee P. Hoefsmit

Figure S2 shows a flowchart of patients PRADO study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23b4f5e8188de09754e20067a2846a84
https://doi.org/10.1158/2767-9764.22348744.v1

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

Autor: Irene L.M. Reijers, Disha Rao, Judith M. Versluis, Alexander M. Menzies, Petros Dimitriadis, Michel W. Wouters, Andrew J. Spillane, Willem M.C. Klop, Annegien Broeks, Linda J.W. Bosch, Marta Lopez-Yurda, Winan J. van Houdt, Robert V. Rawson, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Sten Cornelissen, Jasper Bouwman, Joyce Sanders, Elsemieke Plasmeijer, Yannick S. Elshot, Richard A. Scolyer, Bart A. van de Wiel, Daniel S. Peeper, Alexander C.J. van Akkooi, Georgina V. Long, Christian U. Blank

Publikováno v: Reijers, I L M, Rao, D, Versluis, J M, Menzies, A M, Dimitriadis, P, Wouters, M W, Spillane, A J, Klop, W M C, Broeks, A, Bosch, L J W, Lopez-Yurda, M, van Houdt, W J, Rawson, R V, Grijpink-Ongering, L G, Gonzalez, M, Cornelissen, S, Bouwman, J, Sanders, J, Plasmeijer, E, Elshot, Y S, Scolyer, R A, van de Wiel, B A, Peeper, D S, van Akkooi, A C J, Long, G V & Blank, C U 2023, ' IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma ', Journal of Experimental Medicine, vol. 220, no. 5, e20221952 . https://doi.org/10.1084/jem.20221952
Journal of experimental medicine, 220(5):e20221952. Rockefeller University Press
Journal of Experimental Medicine, 220(5):e20221952. Rockefeller University Press

Neoadjuvant ipilimumab + nivolumab has demonstrated high pathologic response rates in stage III melanoma. Patients with low intra-tumoral interferon-γ (IFN-γ) signatures are less likely to benefit. We show that domatinostat (a class I histone deace

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17999c5aac89a5332bee79a05cb4e596
https://doi.org/10.1084/jem.20221952

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

Autor: Bart A. van de Wiel, Judith M. Versluis, Robyn P. M. Saw, Sydney Ch'ng, C. Blank, Bastian Schilling, Irene L.M. Reijers, Richard A. Scolyer, Georgina V. Long, Michel W.J.M. Wouters, Alexander C.J. van Akkooi, Elisa A. Rozeman, Alexander M. Menzies

Publikováno v: European Journal of Cancer. 148:51-57

Background Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases. Neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and an impre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0cd6cfcc041a55a4244871ca4c62202
https://doi.org/10.1016/j.ejca.2021.02.012